Connection
Rui Zhao to Antineoplastic Agents
This is a "connection" page, showing publications Rui Zhao has written about Antineoplastic Agents.
|
|
Connection Strength |
|
 |
|
 |
|
0.289 |
|
|
|
-
Gardner L, Rossi J, Armstrong B, Muse M, LaVeck A, Blevins MA, Zhang L, Ford HL, Zhao R, Wang X. Rational Design of Novel Allosteric EYA2 Inhibitors as Potential Therapeutics for Multiple Brain Cancers. ChemMedChem. 2024 Sep 16; 19(18):e202400179.
Score: 0.104
-
Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MUJ, Ramirez D, Zhang L, Trinidad-Pineiro J, Mathews Griner L, King R, Barnaeva E, Hu X, Southall NT, Ferrer M, Gustafson DL, Regan DP, D'Alessandro A, Costello JC, Patnaik S, Marugan J, Zhao R, Ford HL. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Res. 2020 06 15; 80(12):2689-2702.
Score: 0.077
-
Blevins MA, Huang M, Zhao R. The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target. Mol Cancer Ther. 2017 06; 16(6):981-990.
Score: 0.063
-
Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, Li X, Ford HL, Zheng W, Zhao R. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. J Biomol Screen. 2013 Jan; 18(1):85-96.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|